Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Dr. Yariv Houvras as chief medical officer.

“We are thrilled to welcome Yariv at this exciting time for Xilio as we advance XTX501, our bispecific PD-1 / masked IL-2, in the clinic and our next generation of multi-specific, masked T cell engagers,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “Yariv is an accomplished physician-scientist with a proven track record of leading complex global clinical development programs from first-in-human studies through registrational Phase 3 trials and regulatory approvals. His deep scientific rigor and expertise in immuno-oncology will be invaluable as we continue towards our goal of unlocking the full potential of our pipeline of masked I-O therapies.”